Lewen -based Augustine therapeutics NVA biotech company was concentrated on developing new therapies for neuromasisitive and cardio-metaphor disease by interrupting the enzymes of Sitosolic Histone Dycitilles 6 (HDAC 6).
Overseascred finances were co-operated by Novo Holdings and Jiteo Capital, supported by the existing investor Asabis Partners, who led the initial € 1.5.5 million dollars in 2021, Eli Lily & Company, AdebO Partners, V-Yo Venses, PMV, PMV, PMV, PMV, PMV, PMV, VIV. CM-based-mitpiton.
Gerahrd QuenigAugustine’s CEO PhD says: “This significant financing is a proof of the innovative Medic Chhatra Chemistry established by Augustine, which works through a unique system of action. The therapeutic potential of HDAC 6 is widely recognized in our industry, but the methods of previous drugs were especially sub-comprised of chronic diseases. In Augustine, we believe that we have solved these challenges with a novel non-hydroxamate, non-hydrazide producing chemotype that avoids the general limits of highly selected and east chemotypes, as therapeutic methods can be avoided by unlocking HDAC 6 inhibition as the therapeutic methodThe
“We are now hoping to quickly advance our leadership candidate in clinical trials for CMT treatment, while our candidates are more wider to change the example of nervous and cardio-metaphor disease. I would like to thank our new and existing investors for their unimaginable assistance as we were moving forward in clinical developmentThe “
Augustine Therapeutics was founded by the VIB-Q Lewen Center for Brain and Disease Research in Belgium in 2019, researching Professor Ludo Van Den Bosh, who identified HDAC 6 Inhibition as a committed method for treating CMT and other neuropathy. Augustine was first seeded by V-Yo Venture, AdeBO Partners, VIB, PMV and Jemma Frisius Fund. The company recently appointed experienced biofamma leader Gerahrd Quenig, PhD, who served as Executive Chairman from June 2021 to lead the company as CEO in January 2021.
Augustine therapeutics is a biotechnology company that focuses on the treatment of neuromasisitive, neurodigening, and cardio-anti-cardiac diseases through its next generation method to prevent selection of HDAC 6. Augustine’s HDAC 6 inhibitors are intentionally stored to preserve its beneficial non-oriented functions to prevent HDAC 6.
HDAC 6 is involved in neurodizenation and tissue aging-related cellular processes, and a pharmacologic inhibition of HDAC 6 is a committed method of several diseases, according to Augustine.
Augustine has been reported to have designed a unique next generation method to prevent selection of HDAC 6 while preserving its beneficial non-agent tasks. This novel is seeking to avoid the constraints of non-hydroxamate, non-hydrazine producing methods, and have significant potential in CMT, the most common hereditary disorder of the peripheral nervous system, which affects about three million people worldwide.
With additional distinct and distinct programs focusing on brain-entertainer and peripheral-symmetric molecules, HDAC 6 inhibitors have more potential in multiple diseases, including neurodizerrative and cardio-metaphoric disorders.
EmanuelPHD, Partner, Seed Investment, Novo Holdings commented: “The mapping of our HDAC6 Eye Landscape has made us confident that molecules have been found with the best-class potential of the innovative and strict approach to Medic Chulkia. HDAC 6 Inhibition shows great promise to many indications and we are persuaded to start our cooperation with the top level management team of Augustine. Furthermore, Augustine will expand its activities in Denmark, a unique ecosystem and talent pool that will support the exploration of HDAC 6 Ai on cardio-metaphorical diseasesThe “
The earnings will be used to advance to AGT-10216, the main candidate of Augustine through the first/II proof-off-concept clinical examination in CMT. Beyond the AGT-200216, there are two more programs in the discovery of the unchanging neurodizerrative and cardio-metabolic hints of Augustine, aimed at the peripheral-seated and blood-brain barrier HDAC 6II.
MehdiSenior Principal of Jiteo Capital Fermd says: “TIn his investment treatment, where patients are limited or have no treatment options, depicts the possibilities of Augustine to bring exciting innovations. To realize the possibility of Augustine, we are delighted to give this financing co-leadership, which stands for both its research quality and the skills of Gerhard and its team. We are waiting for our future cooperation, which shares a common ambition: to accelerate clinical development to bring these innovations to patientsThe “
Senior Principal of Jeito Capital, Fermod, Partner of SID Investments, Envo Holdings, PhD, PhD, Emmanuel Kutotsu, Augustine Therapeutics have joined the board of directors. The operational investor in Jeito Capital will join Annette Clansi and Vice President of the CD Investment, Novo Holdings Board Observer.
[publish_date
